Oral immune‐related adverse events associated with PD‐1 inhibitor therapy: A case series
- 23 October 2019
- journal article
- research article
- Published by Wiley in Oral Diseases
- Vol. 26 (2) , 325-333
Abstract
Objective: The aim of this study was to characterize clinical and histopathological features, and management outcomes of patients with oral immune‐related adverse events (irAEs) secondary to programmed cell death‐1 (PD‐1) inhibitors.Methods: This was a case series of cancer patients receiving PD‐1 inhibitor therapy who were referred to oral medicine for the development of oral irAEs. Demographic, clinical, and histopathological data were collected from electronic medical records.Results: There were 13 patients (7 males) with a median age of 68 years (range: 39–82) who were treated with nivolumab (n = 7) or pembrolizumab (n = 6). Oral irAEs included lichenoid lesions (n = 10), erythema multiforme (EM) (n = 2), and acute graft‐versus‐host disease reactivation (n = 1), with or without ulcerations (n = 8). Four patients (31%) presented with only oral irAEs. Oral biopsies showed lichenoid mucositis (n = 4). Management with topical and systemic steroids led to complete symptomatic response in most patients (n = 12). PD‐1 inhibitor therapy was temporarily discontinued (n = 3) and discontinued indefinitely (n = 2) due to severe oral irAEs.Conclusion: Patients receiving PD‐1 inhibitors may develop oral irAEs characterized by lichenoid lesions, ulcers, or EM. Topical and systemic steroids appear to be effective in managing oral lesions although the severity of irAEs may necessitate PD‐1 inhibitor therapy dose modification.Keywords
This publication has 43 references indexed in Scilit:
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology, 2019
- Liver toxicity in the era of immune checkpoint inhibitors: A practical approachCritical Reviews in Oncology/Hematology, 2018
- Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2018
- FDA Approval Summary: Pembrolizumab for Recurrent Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing PD-L1The Oncologist, 2018
- Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin LymphomaJournal of Clinical Oncology, 2017
- Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer PatientsCancer Immunology Research, 2017
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabAnnals of the Rheumatic Diseases, 2017
- Ipilimumab for Patients with Relapse after Allogeneic TransplantationNew England Journal of Medicine, 2016
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and futureJournal of Clinical Investigation, 2015
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012